Targeting IRAK4 in Chronic Lymphocytic Leukemia
ConditionChronic Lymphocytic Leukemia (CLL)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS San Raffaele
About this trial
Patients with chronic lymphocytic leukemia (CLL) followed at Strategic Research Program on CLL will be enrolled and undergo sampling of additional amount of blood at the time of standard blood tests. Leukemic B cells and peripheral blood mononuclear cells (PBMC).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Diagnosis of CLL
Participant is willing and able to give informed consent for participation in the study.
Disqualifiers
None
Trial population
Adult patients with CLL followed at Strategic Research Program on CLL
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Peripheral blood sample collection
Procedure/SurgeryUp to 50 ml of blood will be collected for the research project at the time of standard blood tests.
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Study cohort1 intervention
Trial outcomes
Primary outcomes
1
TLR signaling
In vitro inhibition of TLR signaling in CLL cells following exposure to IRAK4 CDAC, as assessed by modulation of downstream signaling molecules (e.g. phosphorylation status and/or degradation of key components of the TLR pathway).
Time frame
12 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: